Principal Securities, Inc. Cassava Sciences Inc Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Principal Securities, Inc. holds 25 shares of SAVA stock, worth $93. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25
Previous 25
-0.0%
Holding current value
$93
Previous $59,000
23.73%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
962KPut Options Held
864K-
Black Rock Inc. New York, NY3.22MShares$12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$8.12 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny984KShares$3.68 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$2.95 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$2.29 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $150M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...